These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 29878089)
1. Eldecalcitol Causes FGF23 Resistance for Pi Reabsorption and Improves Rachitic Bone Phenotypes in the Male Hyp Mouse. Kaneko I; Segawa H; Ikuta K; Hanazaki A; Fujii T; Tatsumi S; Kido S; Hasegawa T; Amizuka N; Saito H; Miyamoto KI Endocrinology; 2018 Jul; 159(7):2741-2758. PubMed ID: 29878089 [TBL] [Abstract][Full Text] [Related]
2. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631 [TBL] [Abstract][Full Text] [Related]
3. 1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression. Liu ES; Martins JS; Raimann A; Chae BT; Brooks DJ; Jorgetti V; Bouxsein ML; Demay MB J Bone Miner Res; 2016 May; 31(5):929-39. PubMed ID: 26751835 [TBL] [Abstract][Full Text] [Related]
4. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. Aono Y; Hasegawa H; Yamazaki Y; Shimada T; Fujita T; Yamashita T; Fukumoto S J Bone Miner Res; 2011 Apr; 26(4):803-10. PubMed ID: 20939065 [TBL] [Abstract][Full Text] [Related]
5. Overexpression of human PHEX under the human beta-actin promoter does not fully rescue the Hyp mouse phenotype. Erben RG; Mayer D; Weber K; Jonsson K; Jüppner H; Lanske B J Bone Miner Res; 2005 Jul; 20(7):1149-60. PubMed ID: 15940367 [TBL] [Abstract][Full Text] [Related]
6. Impaired Growth Plate Maturation in XLH Is due to Both Excess FGF23 and Decreased 1,25-Dihydroxyvitamin D Signaling. Yadav PS; Kobelski MM; Martins JS; Tao T; Liu ES; Demay MB Endocrinology; 2023 Nov; 165(1):. PubMed ID: 38066669 [TBL] [Abstract][Full Text] [Related]
7. Comparison of calcimimetic R568 and calcitriol in mineral homeostasis in the Hyp mouse, a murine homolog of X-linked hypophosphatemia. Leifheit-Nestler M; Kucka J; Yoshizawa E; Behets G; D'Haese P; Bergen C; Meier M; Fischer DC; Haffner D Bone; 2017 Oct; 103():224-232. PubMed ID: 28728941 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic Effects of FGF23 c-tail Fc in a Murine Preclinical Model of X-Linked Hypophosphatemia Via the Selective Modulation of Phosphate Reabsorption. Johnson K; Levine K; Sergi J; Chamoun J; Roach R; Vekich J; Favis M; Horn M; Cao X; Miller B; Snyder W; Aivazian D; Reagan W; Berryman E; Colangelo J; Markiewicz V; Bagi CM; Brown TP; Coyle A; Mohammadi M; Magram J J Bone Miner Res; 2017 Oct; 32(10):2062-2073. PubMed ID: 28600887 [TBL] [Abstract][Full Text] [Related]
9. Elevated fibroblast growth factor 23 exerts its effects on placenta and regulates vitamin D metabolism in pregnancy of Hyp mice. Ohata Y; Yamazaki M; Kawai M; Tsugawa N; Tachikawa K; Koinuma T; Miyagawa K; Kimoto A; Nakayama M; Namba N; Yamamoto H; Okano T; Ozono K; Michigami T J Bone Miner Res; 2014 Jul; 29(7):1627-38. PubMed ID: 24470103 [TBL] [Abstract][Full Text] [Related]
10. Vitamin D and type II sodium-dependent phosphate cotransporters. Kido S; Kaneko I; Tatsumi S; Segawa H; Miyamoto K Contrib Nephrol; 2013; 180():86-97. PubMed ID: 23652552 [TBL] [Abstract][Full Text] [Related]
11. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. Yuan B; Takaiwa M; Clemens TL; Feng JQ; Kumar R; Rowe PS; Xie Y; Drezner MK J Clin Invest; 2008 Feb; 118(2):722-34. PubMed ID: 18172553 [TBL] [Abstract][Full Text] [Related]
12. Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice. Martin A; David V; Li H; Dai B; Feng JQ; Quarles LD Mol Endocrinol; 2012 Nov; 26(11):1883-95. PubMed ID: 22930691 [TBL] [Abstract][Full Text] [Related]
13. FGF23-induced hypophosphatemia persists in Hyp mice deficient in the WNT coreceptor Lrp6. Uchihashi K; Nakatani T; Goetz R; Mohammadi M; He X; Razzaque MS Contrib Nephrol; 2013; 180():124-37. PubMed ID: 23652555 [TBL] [Abstract][Full Text] [Related]
14. Sclerostin Antibody Treatment Increases Bone Mass and Normalizes Circulating Phosphate Levels in Growing Hyp Mice. Carpenter KA; Ross RD J Bone Miner Res; 2020 Mar; 35(3):596-607. PubMed ID: 31743490 [TBL] [Abstract][Full Text] [Related]
15. Sclerostin antibody improves phosphate metabolism hormones, bone formation rates, and bone mass in adult Hyp mice. Carpenter KA; Davison R; Shakthivel S; Anderson KD; Ko FC; Ross RD Bone; 2022 Jan; 154():116201. PubMed ID: 34537437 [TBL] [Abstract][Full Text] [Related]
16. Pathogenic role of Fgf23 in Hyp mice. Liu S; Zhou J; Tang W; Jiang X; Rowe DW; Quarles LD Am J Physiol Endocrinol Metab; 2006 Jul; 291(1):E38-49. PubMed ID: 16449303 [TBL] [Abstract][Full Text] [Related]
17. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model. Nakatani T; Ohnishi M; Razzaque MS FASEB J; 2009 Nov; 23(11):3702-11. PubMed ID: 19584304 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. Aono Y; Yamazaki Y; Yasutake J; Kawata T; Hasegawa H; Urakawa I; Fujita T; Wada M; Yamashita T; Fukumoto S; Shimada T J Bone Miner Res; 2009 Nov; 24(11):1879-88. PubMed ID: 19419316 [TBL] [Abstract][Full Text] [Related]
19. Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice. Zhang MY; Ranch D; Pereira RC; Armbrecht HJ; Portale AA; Perwad F Endocrinology; 2012 Apr; 153(4):1806-16. PubMed ID: 22334725 [TBL] [Abstract][Full Text] [Related]
20. Effects of Active Vitamin D or FGF23 Antibody on Lira Dos Santos EJ; Chavez MB; Tan MH; Mohamed FF; Kolli TN; Foster BL; Liu ES J Dent Res; 2021 Dec; 100(13):1482-1491. PubMed ID: 33906518 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]